Omni Ab Status
The company was acquired by Ligand Pharmaceuticals (NAS:LGND) for $178 million on December 29, 2015. The deal included $92.6 million in cash and $85.4 million in Ligand common stock.
Developer of human monoclonal antibody platforms. The company develops human therapeutic antibodies based on transgenic rats for pharmaceutical companies.
Year Founded
2007
General Information
-
Website
-
Business Status
Profitable
-
Ownership Status
Acquired/Merged (Operating Subsidiary)
-
Financing Status
Formerly VC-backed
Omni Ab News and Updates
Digital Investments & Premiumization to Aid AB InBev (BUD)
Nasdaq | September 29, 2022
Sweden's Westpay Enlists ACI Worldwide to Offer Omni-Commerce Payments to Merchants
Yahoo Finance | September 26, 2022
2022 Fall Preview: News, Food, and Notable Memoirs
Quill & Quire | September 21, 2022
The top industries and employers in the Asheville, NC metro area
AVLtoday | September 21, 2022
Assemblymember Friedman's Omni-Bike Bill AB 1909 Signed by Governor Newsom
MyBurbank.com | September 19, 2022
Omni Ab Primary Industry Sector / Group / Code
Omni Ab's Trends
Headquarters
-
HQ Address Line 12747 Ross Road
-
HQ Address Line 2Suite A
-
HQ CityPalo Alto
-
HQ State/ProvinceCalifornia
-
HQ Post Code94303
-
HQ CountryUnited States
Omni Ab's Keywords
mood_badFeed is empty.
Add a review